Structure of human monoamine oxidase B, a drug targe neurological disorders

Nature Structural Biology 9, 22-26

DOI: 10.1038/nsb732

Citation Report

#	Article	IF	CITATIONS
1	Monoamine oxidase inhibitors. Expert Opinion on Therapeutic Patents, 2002, 12, 1813-1829.	2.4	3
2	Structure-Function Relationships in Flavoenzyme-dependent Amine Oxidations. Journal of Biological Chemistry, 2002, 277, 23973-23976.	1.6	152
3	STUDIES ON THE OXIDATION OF 1,4-DISUBSTITUTED-1,2,3,6-TETRAHYDROPYRIDINES. Drug Metabolism Reviews, 2002, 34, 533-547.	1.5	5
4	Analysis of Conserved Active Site Residues in Monoamine Oxidase A and B and Their Three-dimensional Molecular Modeling. Journal of Biological Chemistry, 2002, 277, 17209-17216.	1.6	70
5	Overexpression of Membrane Proteins Using Pichia pastoris. Current Protocols in Protein Science, 2002, 29, Unit 29.2.	2.8	11
6	Analysis of the roles of amino acid residues in the flavoprotein tryptophan 2-monooxygenase modified by 2-oxo-3-pentynoate: characterization of His338, Cys339, and Cys511 mutant enzymes. Archives of Biochemistry and Biophysics, 2002, 402, 24-30.	1.4	12
7	8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism. Journal of Biological Chemistry, 2002, 277, 36040-36044.	1.6	103
9	Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. synthesis and SAR studies. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3551-3555.	1.0	87
10	Inhibitors alter the spectrum and redox properties of monoamine oxidase A. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2002, 1601, 178-184.	1.1	21
11	Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3629-3633.	1.0	98
12	Loss of spr-5 bypasses the requirement for the C.elegans presenilin sel-12 by derepressing hop-1. EMBO Journal, 2002, 21, 5787-5796.	3.5	57
13	Interactions of D-amphetamine with the active site of monoamine oxidase-A. Inflammopharmacology, 2003, 11, 127-133.	1.9	4
14	Molecules. Drug Discovery Today, 2003, 8, 275-276.	3.2	0
15	Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochemical Pharmacology, 2003, 65, 1867-1874.	2.0	18
16	Synthesis and in vitro biological evaluation of fluoro-substituted-4-phenyl-1,2,3,6-tetrahydropyridines as monoamine oxidase B substrates. Bioorganic and Medicinal Chemistry, 2003, 11, 5229-5234.	1.4	29
17	Inhibition of monoamine oxidase B by selective adenosine A 2A receptor antagonists. Bioorganic and Medicinal Chemistry, 2003, 11, 1299-1310.	1.4	97
18	Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. Bioorganic and Medicinal Chemistry, 2003, 11, 4423-4430.	1.4	17
19	Deflavination and reconstitution of flavoproteins. FEBS Journal, 2003, 270, 4227-4242.	0.2	110

TATION RED

#	Article	IF	CITATIONS
20	Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 69-73.	1.0	17
21	Simple, Potent, and Selective Pyrrole Inhibitors of Monoamine Oxidase Types A and B. Journal of Medicinal Chemistry, 2003, 46, 917-920.	2.9	47
22	The expression of outer membrane proteins for crystallization. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1610, 37-45.	1.4	72
23	Membrane protein structural biology: the high throughput challenge. Journal of Structural Biology, 2003, 142, 144-153.	1.3	154
24	Structural Comparison of Human Monoamine Oxidases A and B. Journal of Biological Chemistry, 2003, 278, 28612-28618.	1.6	41
25	Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9750-9755.	3.3	360
26	Cloning, Sequencing, and Heterologous Expression of the Murine Peroxisomal Flavoprotein, N1-Acetylated Polyamine Oxidase. Journal of Biological Chemistry, 2003, 278, 20514-20525.	1.6	104
27	Mouse spermine oxidase gene splice variants. FEBS Journal, 2004, 271, 760-770.	0.2	60
28	Crystal structure of protoporphyrinogen IX oxidase: a key enzyme in haem and chlorophyll biosynthesis. EMBO Journal, 2004, 23, 1720-1728.	3.5	226
29	Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. British Journal of Pharmacology, 2004, 143, 495-507.	2.7	22
30	Synthesis and Selective Inhibitory Activity of 1-Acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole Derivatives against Monoamine Oxidase. Journal of Medicinal Chemistry, 2004, 47, 2071-2074.	2.9	105
31	Positive selection in MAOA gene is human exclusive: determination of the putative amino acid change selected in the human lineage. Human Genetics, 2004, 115, 377-86.	1.8	36
32	Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3697-3703.	1.0	89
33	Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Journal of Neurochemistry, 2004, 86, 290-297.	2.1	53
34	Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?. BioEssays, 2004, 26, 80-90.	1.2	54
35	Fluorinated Phenylcyclopropylamines as Inhibitors of Monoamine Oxidases. ChemBioChem, 2004, 5, 1033-1043.	1.3	30
36	Carbanion versus hydride transfer mechanisms in flavoprotein-catalyzed dehydrogenations. Bioorganic Chemistry, 2004, 32, 125-139.	2.0	77
37	Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Analytical Biochemistry, 2004, 333, 79-87	1.1	18

#	Article	IF	CITATIONS
38	Overview of Protein Structural and Functional Folds. Current Protocols in Protein Science, 2004, 35, Unit 17.1.	2.8	25
39	Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the N-Propargylaminoindan Class. Journal of Medicinal Chemistry, 2004, 47, 1767-1774.	2.9	200
40	Inactivation of Purified Human Recombinant Monoamine Oxidases A and B by Rasagiline and Its Analogues. Journal of Medicinal Chemistry, 2004, 47, 1760-1766.	2.9	86
41	Structural commonalities among integral membrane enzymes. FEBS Letters, 2004, 567, 159-165.	1.3	44
42	Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochimica Et Biophysica Acta - General Subjects, 2004, 1672, 60-66.	1.1	22
43	The circadian rhythm of 5-HT biosynthetic and degradative enzymes in immortalized mouse neuroendocrine pineal cell line–a model for studying circadian rhythm. Life Sciences, 2004, 75, 3017-3026.	2.0	3
44	Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors. Journal of Molecular Biology, 2004, 338, 103-114.	2.0	198
45	Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Letters, 2004, 564, 225-228.	1.3	100
46	Conserved Elements of the Cytochrome P-450 Superfamily Found in Monoamine Oxidase B. NeuroToxicology, 2004, 25, 73-78.	1.4	0
47	Computer Modelling and Visualization of Active Site of Monoamine Oxidases. NeuroToxicology, 2004, 25, 37-46.	1.4	16
48	Modeling of Human Monoamine Oxidase A: From Low Resolution Threading Models to Accurate Comparative Models Based on Crystal Structures. NeuroToxicology, 2004, 25, 47-61.	1.4	2
49	On the Binding of Monoamine Oxidase Inhibitors to Some Sites Distinct from the MAO Active Site, and Effects Thereby Elicited. NeuroToxicology, 2004, 25, 251-266.	1.4	41
50	Cloning, After Cloning, Knock-out Mice, and Physiological Functions of MAO A and B. NeuroToxicology, 2004, 25, 21-30.	1.4	77
51	The FAD Binding Sites of Human Monoamine Oxidases A and B. NeuroToxicology, 2004, 25, 63-72.	1.4	76
52	Spectral and catalytic properties of aryl-alcohol oxidase, a fungal flavoenzyme acting on polyunsaturated alcohols. Biochemical Journal, 2005, 389, 731-738.	1.7	79
53	Flavoenzyme catalysed oxidation of amines: roles for flavin and protein-based radicals. Biochemical Society Transactions, 2005, 33, 754-757.	1.6	16
54	Examination of mitochondrial protein targeting of haem synthetic enzymes: in vivo identification of three functional haem-responsive motifs in 5-aminolaevulinate synthase. Biochemical Journal, 2005, 386, 381-386.	1.7	59
55	Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorganic and Medicinal Chemistry, 2005, 13, 3487-3495.	1.4	43

	CITATION	Report	
#	Article	IF	CITATIONS
56	Heteroarylisopropylamines as MAO inhibitors. Bioorganic and Medicinal Chemistry, 2005, 13, 4450-4457.	1.4	33
57	Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity. Bioorganic and Medicinal Chemistry, 2005, 13, 4777-4788.	1.4	83
58	Docking studies on monoamine oxidase-B inhibitors: Estimation of inhibition constants (Ki) of a series of experimentally tested compounds. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4438-4446.	1.0	49
59	Membranes are more mosaic than fluid. Nature, 2005, 438, 578-580.	13.7	776
60	Two short protein domains are responsible for the nuclear localization of the mouse spermine oxidase µ isoform. FEBS Journal, 2005, 272, 3052-3059.	2.2	20
61	Characterisation of imidazoline I2 binding sites in pig brain. European Journal of Pharmacology, 2005, 519, 68-74.	1.7	10
62	Orientation of oxazolidinones in the active site of monoamine oxidase. Biochemical Pharmacology, 2005, 70, 407-416.	2.0	23
63	Synthesis of Novel N-Substituted Imidazolecarboxylic Acid Hydrazides as Monoamine Oxidase Inhibitors. Il Farmaco, 2005, 60, 237-240.	0.9	7
64	Directed Evolution of an Amine Oxidase for the Preparative Deracemisation of Cyclic Secondary Amines. ChemBioChem, 2005, 6, 637-639.	1.3	121
65	Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1550-1562.	2.5	65
66	Demonstration of Isoleucine 199 as a Structural Determinant for the Selective Inhibition of Human Monoamine Oxidase B by Specific Reversible Inhibitors. Journal of Biological Chemistry, 2005, 280, 15761-15766.	1.6	189
67	Structure and activity of the axon guidance protein MICAL. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16830-16835.	3.3	74
68	A Stable Tyrosyl Radical in Monoamine Oxidase A. Journal of Biological Chemistry, 2005, 280, 4627-4631.	1.6	45
69	Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole Derivatives. Journal of Medicinal Chemistry, 2005, 48, 7113-7122.	2.9	112
70	Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12684-12689.	3.3	446
71	Lys300 Plays a Major Role in the Catalytic Mechanism of Maize Polyamine Oxidaseâ€. Biochemistry, 2005, 44, 16108-16120.	1.2	48
72	pH and Kinetic Isotope Effects on Sarcosine Oxidation byN-Methyltryptophan Oxidaseâ€. Biochemistry, 2005, 44, 3074-3081.	1.2	21
73	Design, Synthesis, and Biological Activities of Pyrrolylethanoneamine Derivatives, a Novel Class of Monoamine Oxidases Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4220-4223.	2.9	37

#	Article	IF	CITATIONS
74	Mechanistic Studies of Mouse Polyamine Oxidase with N1,N12-Bisethylspermine as a Substrateâ€. Biochemistry, 2005, 44, 7079-7084.	1.2	23
75	Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A. Journal of Medicinal Chemistry, 2005, 48, 499-506.	2.9	282
76	Molecular characterization of monoamine oxidase in zebrafish (Danio rerio). Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2005, 140, 153-161.	0.7	66
77	Expression of G protein coupled receptors in a cell-free translational system using detergents and thioredoxin-fusion vectors. Protein Expression and Purification, 2005, 41, 27-37.	0.6	170
78	Cloning and characterization of histamine dehydrogenase from Nocardioides simplex. Archives of Biochemistry and Biophysics, 2005, 436, 8-22.	1.4	24
79	Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches. Journal of Medicinal Chemistry, 2006, 49, 4912-4925.	2.9	104
80	A Computational Protocol for the Integration of the Monotopic Protein Prostaglandin H2 Synthase into a Phospholipid Bilayer. Biophysical Journal, 2006, 91, 401-410.	0.2	21
81	A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism. Organic and Biomolecular Chemistry, 2006, 4, 646.	1.5	54
82	Mechanistic Studies of the Flavoenzyme Tryptophan 2-Monooxygenase:Â Deuterium and15N Kinetic Isotope Effects on Alanine Oxidation by anl-Amino Acid Oxidaseâ€. Biochemistry, 2006, 45, 15844-15852.	1.2	47
83	NMR Structure and Molecular Dynamics of the In-Plane Membrane Anchor of Nonstructural Protein 5A from Bovine Viral Diarrhea Virus,. Biochemistry, 2006, 45, 2221-2233.	1.2	53
84	Functional Role of the "Aromatic Cage―in Human Monoamine Oxidase B:  Structures and Catalytic Properties of Tyr435 Mutant Proteins,. Biochemistry, 2006, 45, 4775-4784.	1.2	127
85	Synthesis and Molecular Modelling of Novel Substituted-4,5-dihydro-(1H)-pyrazole Derivatives as Potent and Highly Selective Monoamine Oxidase-A Inhibitors. Chemical Biology and Drug Design, 2006, 67, 206-214.	1.5	26
86	The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience, 2006, 7, 295-309.	4.9	1,163
87	Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N′-bis[2-oxo-2H-benzopyran]-3-carboxamides. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4135-4140.	1.0	28
88	Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorganic and Medicinal Chemistry, 2006, 14, 3392-3398.	1.4	46
89	Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorganic and Medicinal Chemistry, 2006, 14, 3512-3521.	1.4	71
90	Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. Computational and Theoretical Chemistry, 2006, 767, 3-9.	1.5	67
91	Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. , 2006, , 53-65.		100

#	Article	IF	CITATIONS
92	Some Properties of Interfacial Water: Determinants for Cell Architecture and Function?. , 2006, , 253-272.		22
93	Quercetin as the Active Principle ofHypericumhircinumExerts a Selective Inhibitory Activity against MAO-A:Â Extraction, Biological Analysis, and Computational Study. Journal of Natural Products, 2006, 69, 945-949.	1.5	118
94	Amine oxidases in apoptosis and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1765, 1-13.	3.3	47
95	A Monotopic Membrane Protein Goes Solo. Structure, 2006, 14, 628-629.	1.6	4
96	To be or not to be an oxidase: challenging the oxygen reactivity of flavoenzymes. Trends in Biochemical Sciences, 2006, 31, 276-283.	3.7	248
97	Lipophilicity Plays a Major Role in Modulating the Inhibition of Monoamine Oxidase B by 7-Substituted Coumarins. Chemistry and Biodiversity, 2006, 3, 134-149.	1.0	52
98	Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio). Journal of Comparative Neurology, 2006, 498, 593-610.	0.9	80
99	Designer short peptide surfactants stabilize G protein-coupled receptor bovine rhodopsin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17707-17712.	3.3	159
100	Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13956-13961.	3.3	248
102	Parkin Suppresses the Expression of Monoamine Oxidases. Journal of Biological Chemistry, 2006, 281, 8591-8599.	1.6	71
103	Structure and Mechanism of Lysine-specific Demethylase Enzymes. Journal of Biological Chemistry, 2007, 282, 35425-35429.	1.6	114
104	Drug Metabolism. , 2007, , .		8
105	Genome-Wide Dynamics of SAPHIRE, an Essential Complex for Gene Activation and Chromatin Boundaries. Molecular and Cellular Biology, 2007, 27, 4058-4069.	1.1	24
106	Renalase, a new renal hormone: its role in health and disease. Current Opinion in Nephrology and Hypertension, 2007, 16, 373-378.	1.0	52
107	In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: Evidence for two distinct I2 binding sites. Neuropharmacology, 2007, 52, 395-404.	2.0	13
108	Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Archives of Biochemistry and Biophysics, 2007, 464, 269-276.	1.4	177
109	Molecular docking of inhibitors into monoamine oxidase B. Biochemical and Biophysical Research Communications, 2007, 360, 401-406.	1.0	21
110	Monoamine oxidase and tobacco dependence. NeuroToxicology, 2007, 28, 182-195.	1.4	113

#	Article	IF	CITATIONS
111	Renalase is a novel renal hormone that regulates cardiovascular function. Journal of the American Society of Hypertension, 2007, 1, 99-103.	2.3	38
112	Monoamine Oxidase Isoform-Dependent Tautomeric Influence in the Recognition of 3,5-Diaryl Pyrazole Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 425-428.	2.9	65
113	Monotopic Enzymes and Lipid Bilayers: A Comparative Studyâ€. Biochemistry, 2007, 46, 3108-3115.	1.2	36
114	Insights into the Mechanism of Flavoprotein-Catalyzed Amine Oxidation from Nitrogen Isotope Effects on the Reaction of N-Methyltryptophan Oxidase. Biochemistry, 2007, 46, 7655-7664.	1.2	69
115	Solid-Phase Synthesis and Insights into Structureâ^'Activity Relationships of Safinamide Analogues as Potent and Selective Inhibitors of Type B Monoamine Oxidase. Journal of Medicinal Chemistry, 2007, 50, 4909-4916.	2.9	49
116	Selective Inhibitory Activity against MAO and Molecular Modeling Studies of 2-Thiazolylhydrazone Derivatives. Journal of Medicinal Chemistry, 2007, 50, 707-712.	2.9	79
117	Novel Substituted (Pyridin-3-yl)phenyloxazolidinones:  Antibacterial Agents with Reduced Activity against Monoamine Oxidase A and Increased Solubility. Journal of Medicinal Chemistry, 2007, 50, 4868-4881.	2.9	38
118	Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs. Journal of Medicinal Chemistry, 2007, 50, 5848-5852.	2.9	472
119	Characterization of the Covalently Bound Anionic Flavin Radical in Monoamine Oxidase A by Electron Paramagnetic Resonance. Journal of the American Chemical Society, 2007, 129, 16091-16097.	6.6	44
120	New Pyrrole Inhibitors of Monoamine Oxidase:Â Synthesis, Biological Evaluation, and Structural Determinants of MAO-A and MAO-B Selectivity. Journal of Medicinal Chemistry, 2007, 50, 922-931.	2.9	114
121	Principles of Drug Metabolism 1: Redox Reactions. , 2007, , 87-132.		13
122	Synthesis and Monoamine Oxidase Inhibitory Activity of New Pyridazine-, Pyrimidine- and 1,2,4-Triazine-Containing Tricyclic Derivatives. Journal of Medicinal Chemistry, 2007, 50, 5364-5371.	2.9	37
123	Enantioselective oxidation of O-methyl-N-hydroxylamines using monoamine oxidase N as catalyst. Chemical Communications, 2007, , 1530.	2.2	30
124	Monoamine Oxidases. , 2007, , 1-5.		1
125	Insights into the mechanisms of flavoprotein oxidases from kinetic isotope effects. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 1016-1025.	0.5	21
126	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: Insights from molecular modeling studies. Bioorganic and Medicinal Chemistry, 2007, 15, 5198-5206.	1.4	21
127	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology, 2007, 152, 946-951.	2.7	208
128	Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS Journal, 2007, 274, 1567-1575.	2.2	23

#	Article	IF	CITATIONS
129	The aromatic cage in the active site of monoamine oxidase B: effect on the structural and electronic properties of bound benzylamine and p-nitrobenzylamine. Journal of Neural Transmission, 2007, 114, 693-698.	1.4	48
130	New insights into the structures and functions of human monoamine oxidases A and B. Journal of Neural Transmission, 2007, 114, 703-705.	1.4	31
131	Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better. Journal of Neural Transmission, 2007, 114, 707-712.	1.4	43
132	Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties. Journal of Neural Transmission, 2007, 114, 725-732.	1.4	23
133	Discovery and characterization of a putrescine oxidase from Rhodococcus erythropolis NCIMB 11540. Applied Microbiology and Biotechnology, 2008, 78, 455-463.	1.7	36
134	Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of variants of monoamine oxidase fromAspergillus niger. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 182-185.	0.7	31
135	Synthesis and Monoamine Oxidase Inhibitory Activities of 1â€Thiocarbamoylâ€3,5â€diphenylâ€4,5â€dihydroâ€1 <i>H</i> â€pyrazole Derivatives. Archiv Der Pharmazie, 200 209-215.)82 3 41,	27
136	Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. European Journal of Medicinal Chemistry, 2008, 43, 2262-2267.	2.6	46
137	The tert-butoxyl radical mediated hydrogen atom transfer reactions of the Parkinsonian proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and selected tertiary amines. Bioorganic and Medicinal Chemistry, 2008, 16, 8557-8562.	1.4	13
138	Synthesis, structure–activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorganic and Medicinal Chemistry, 2008, 16, 9729-9740.	1.4	31
139	Monoamine oxidase inactivation: From pathophysiology to therapeutics. Advanced Drug Delivery Reviews, 2008, 60, 1527-1533.	6.6	490
140	Nuclear localization of human spermine oxidase isoforms – possible implications in drug response and disease etiology. FEBS Journal, 2008, 275, 2795-2806.	2.2	56
141	The pH dependence of kinetic isotope effects in monoamine oxidase A indicates stabilization of the neutral amine in the enzyme–substrate complex. FEBS Journal, 2008, 275, 3850-3858.	2.2	57
142	Overcoming the challenges of membrane protein crystallography. Current Opinion in Structural Biology, 2008, 18, 581-586.	2.6	419
143	Molecular Dynamics, Flexible Docking, Virtual Screening, ADMET Predictions, and Molecular Interaction Field Studies to Design Novel Potential MAO-B Inhibitors. Journal of Biomolecular Structure and Dynamics, 2008, 25, 347-355.	2.0	40
144	Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B. Journal of Medicinal Chemistry, 2008, 51, 8019-8026.	2.9	45
145	The Structure of Monoamine Oxidase from Aspergillus niger Provides a Molecular Context for Improvements in Activity Obtained by Directed Evolution. Journal of Molecular Biology, 2008, 384, 1218-1231.	2.0	76
146	Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris. Protein Expression and Purification, 2008, 59, 349-356.	0.6	10

#	Article	IF	CITATIONS
147	Synthesis, Stereochemical Identification, and Selective Inhibitory Activity against Human Monoamine Oxidase-B of 2-Methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. Journal of Medicinal Chemistry, 2008, 51, 4874-4880.	2.9	86
148	Structural and Mechanistic Studies of Arylalkylhydrazine Inhibition of Human Monoamine Oxidases A and B. Biochemistry, 2008, 47, 5616-5625.	1.2	70
149	Comparison of the Structural Properties of the Active Site Cavities of Human and Rat Monoamine Oxidase A and B in Their Soluble and Membrane-Bound Forms. Biochemistry, 2008, 47, 526-536.	1.2	22
150	Determination of the Oligomeric States of Human and Rat Monoamine Oxidases in the Outer Mitochondrial Membrane and Octyl β- <scp>d</scp> -Glucopyranoside Micelles Using Pulsed Dipolar Electron Spin Resonance Spectroscopy. Biochemistry, 2008, 47, 1554-1566.	1.2	57
151	Structure of human monoamine oxidase A at 2.2-â,,« resolution: The control of opening the entry for substrates/inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5739-5744.	3.3	485
152	ADP Competes with FAD Binding in Putrescine Oxidase. Journal of Biological Chemistry, 2008, 283, 28259-28264.	1.6	9
153	Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A Receptors for Parkinson's Disease. Neurotherapeutics, 2009, 6, 141-151.	2.1	74
154	Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 6761-6772.	1.4	34
155	Effect of shortâ€ŧime exposures to nickel and lead on brain monoamine oxidase from <i>Danio rerio</i> and <i>Poecilia reticulata</i> . Environmental Toxicology, 2009, 24, 309-313.	2.1	12
156	<i>Thermo</i> FAD, a <i>Thermofluor</i> ^{<i>®</i>} â€adapted flavin <i>ad hoc</i> detection system for protein folding and ligand binding. FEBS Journal, 2009, 276, 2833-2840.	2.2	166
157	New roles of flavoproteins in molecular cell biology: Histone demethylase LSD1 and chromatin. FEBS Journal, 2009, 276, 4304-4312.	2.2	71
158	New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Bioorganic and Medicinal Chemistry, 2009, 17, 675-689.	1.4	133
159	Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 2452-2460.	1.4	28
160	Inhibition of monoamine oxidase B by N-methyl-2-phenylmaleimides. Bioorganic and Medicinal Chemistry, 2009, 17, 3104-3110.	1.4	18
161	Ultrasound promoted synthesis of 2-imidazolines in water: A greener approach toward monoamine oxidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 546-549.	1.0	50
162	A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3268-3270.	1.0	124
163	Mechanistic Studies of <i>para</i> -Substituted <i>N</i> , <i>N</i> ′-Dibenzyl-1,4-diaminobutanes as Substrates for a Mammalian Polyamine Oxidase. Biochemistry, 2009, 48, 12305-12313.	1.2	14
164	Use of pH and Kinetic Isotope Effects To Establish Chemistry as Rate-Limiting in Oxidation of a Peptide Substrate by LSD1. Biochemistry, 2009, 48, 5440-5445.	1.2	33

#	Article	IF	CITATIONS
165	pH Dependence of a Mammalian Polyamine Oxidase: Insights into Substrate Specificity and the Role of Lysine 315. Biochemistry, 2009, 48, 1508-1516.	1.2	38
166	Development of Spin-Labeled Pargyline Analogues as Specific Inhibitors of Human Monoamine Oxidases A and B. Biochemistry, 2009, 48, 3928-3935.	1.2	17
167	Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2 <i>H</i> -chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor. Journal of Medicinal Chemistry, 2009, 52, 6685-6706.	2.9	100
168	Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2818-2824.	2.9	162
169	Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases. Biochemistry, 2009, 48, 4220-4230.	1.2	258
170	Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). Free Radical Research, 2009, 43, 975-984.	1.5	16
171	Redox Control of Protein Conformation in Flavoproteins. Antioxidants and Redox Signaling, 2009, 11, 1741-1766.	2.5	50
172	Synthesis, Molecular Modeling, and Selective Inhibitory Activity against Human Monoamine Oxidases of 3-Carboxamido-7-Substituted Coumarins. Journal of Medicinal Chemistry, 2009, 52, 1935-1942.	2.9	152
173	Mitochondria and vascular pathology. Pharmacological Reports, 2009, 61, 123-130.	1.5	88
174	Membrane Attachment Facilitates Ligand Access to the Active Site in Monoamine Oxidase A. Biochemistry, 2009, 48, 5864-5873.	1.2	14
175	Monoamine Oxidase Inhibitors: Benzylidene-prop-2-ynyl-amines Analogues. Biological and Pharmaceutical Bulletin, 2010, 33, 725-728.	0.6	4
176	Structures of membrane proteins. Quarterly Reviews of Biophysics, 2010, 43, 65-158.	2.4	157
177	Rapid screening of monoamine oxidase B inhibitors in natural extracts by capillary electrophoresis after enzymatic reaction at capillary inlet. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3156-3160.	1.2	25
178	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1659-1664.	1.4	19
179	Tyrosyl Radical Formation and Propagation in Flavin Dependent Monoamine Oxidases. ChemBioChem, 2010, 11, 1228-1231.	1.3	25
180	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1388-1395.	1.4	39
181	Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 5063-5070.	1.4	44
182	Predictive screening model for potential vector-mediated transport of cationic substrates at the blood–brain barrier choline transporter. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 870-877.	1.0	19

#	Article	IF	CITATIONS
183	â€~Click' assembly of selective inhibitors for MAO-A. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6222-6225.	1.0	35
184	Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1 H)-pyrazole derivatives. European Journal of Medicinal Chemistry, 2010, 45, 800-804.	2.6	84
185	Monoamine Oxidases and Flavin-Containing Monooxygenases. , 2010, , 77-110.		4
186	Synthesis, in Vitro Activity, and Three-Dimensional Quantitative Structureâ^'Activity Relationship of Novel Hydrazine Inhibitors of Human Vascular Adhesion Protein-1. Journal of Medicinal Chemistry, 2010, 53, 6301-6315.	2.9	26
187	A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole. Analyst, The, 2010, 135, 1779.	1.7	29
188	Cluster Formation of Anchored Proteins Induced by Membrane-Mediated Interaction. Biophysical Journal, 2010, 98, 2554-2563.	0.2	41
189	On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B. Pharmacological Research, 2010, 62, 475-488.	3.1	46
190	Flavin-Dependent Enzymes. , 2010, , 37-113.		57
191	Crystal Structure Analysis of Free and Substrate-Bound 6-Hydroxy-l-Nicotine Oxidase from Arthrobacter nicotinovorans. Journal of Molecular Biology, 2010, 396, 785-799.	2.0	33
192	Molecular characteristics of a single and novel form of carp (Cyprinus carpio) monoamine oxidase. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2010, 155, 266-271.	0.7	3
193	High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: Comparison with human MAO A. Protein Expression and Purification, 2010, 70, 211-217.	0.6	18
194	Oxidation of amines by flavoproteins. Archives of Biochemistry and Biophysics, 2010, 493, 13-25.	1.4	189
195	A lysine conserved in the monoamine oxidase family is involved in oxidation of the reduced flavin in mouse polyamine oxidase. Archives of Biochemistry and Biophysics, 2010, 498, 83-88.	1.4	40
196	The Degradation of Serotonin: Role of MAO. Handbook of Behavioral Neuroscience, 2010, 21, 203-218.	0.7	16
197	Insights on the Mechanism of Amine Oxidation Catalyzed by <scp>d</scp> -Arginine Dehydrogenase Through pH and Kinetic Isotope Effects. Journal of the American Chemical Society, 2011, 133, 18957-18965.	6.6	20
198	Structures and mechanism of the monoamine oxidase family. Biomolecular Concepts, 2011, 2, 365-377.	1.0	166
199	Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Molecular Psychiatry, 2011, 16, 867-880.	4.1	260
200	Structural properties of human monoamine oxidases A and B. International Review of Neurobiology, 2011, 100, 1-11.	0.9	55

#	Article	IF	CITATIONS
201	Detecting Nanodomains in Living Cell Membrane by Fluorescence Correlation Spectroscopy. Annual Review of Physical Chemistry, 2011, 62, 417-436.	4.8	131
202	Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. International Review of Neurobiology, 2011, 100, 13-42.	0.9	98
203	Steered Molecular Dynamics Simulations Reveal Important Mechanisms in Reversible Monoamine Oxidase B Inhibition. Biochemistry, 2011, 50, 6441-6454.	1.2	23
204	Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): Comparisons with human MAO A and MAO B. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2011, 159, 78-83.	0.7	25
205	Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1 <i>H</i> -Pyrrol-3-yl)-2-oxazolidinones. Journal of Medicinal Chemistry, 2011, 54, 8228-8232.	2.9	33
206	The Effects of Gold and Silver Nanoparticles on Choline Estrase and Monoamino Oxidase Enzymes Activities. International Journal of Chemistry, 2011, 3, .	0.3	5
207	Catalytic Mechanism Investigation of Lysine-Specific Demethylase 1 (LSD1): A Computational Study. PLoS ONE, 2011, 6, e25444.	1.1	42
209	Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2011, 46, 4665-4668.	2.6	60
210	Monoamine oxidase inhibition by selected anilide derivatives. European Journal of Medicinal Chemistry, 2011, 46, 5162-5174.	2.6	31
211	Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase. Bioorganic and Medicinal Chemistry, 2011, 19, 7507-7518.	1.4	29
212	Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines. Bioorganic and Medicinal Chemistry, 2011, 19, 7482-7492.	1.4	18
213	Synthesis and Study of a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 7127-7137.	2.9	147
214	Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorganic and Medicinal Chemistry, 2011, 19, 261-274.	1.4	71
215	Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. Bioorganic and Medicinal Chemistry, 2011, 19, 4829-4840.	1.4	37
216	Irreversible Inhibition of Monoamine Oxidase B by the Antiparkinsonian Medicines Rasagiline and Selegiline: A Computational Study. European Journal of Organic Chemistry, 2011, 2011, 6419-6433.	1.2	32
217	Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives. European Journal of Medicinal Chemistry, 2011, 46, 1147-1152.	2.6	65
218	8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. European Journal of Medicinal Chemistry, 2011, 46, 3474-3485.	2.6	28
219	Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Human Molecular Genetics, 2011, 20, 1074-1083.	1.4	61

#	Article	IF	CITATIONS
220	Functional diversity inside the Arabidopsis polyamine oxidase gene family. Journal of Experimental Botany, 2011, 62, 1155-1168.	2.4	140
221	Crystallographic snapshots of the complete reaction cycle of nicotine degradation by an amine oxidase of the monoamine oxidase (MAO) family. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4800-4805.	3.3	26
222	Focusing on New Monoamine Oxidase Inhibitors: Differently Substituted Coumarins As An Interesting Scaffold. Current Topics in Medicinal Chemistry, 2012, 12, 2210-2239.	1.0	68
223	Predicting Monoamine Oxidase Inhibitory Activity Through Ligand-Based Models. Current Topics in Medicinal Chemistry, 2012, 12, 2258-2274.	1.0	19
225	Synthesis of New 7-Oxycoumarin Derivatives As Potent and Selective Monoamine Oxidase A Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 10424-10436.	2.9	36
226	Selected C7-substituted chromone derivatives as monoamine oxidase inhibitors. Bioorganic Chemistry, 2012, 45, 1-11.	2.0	52
227	Analytical Approaches for Studying Transporters, Channels and Porins. Chemical Reviews, 2012, 112, 6227-6249.	23.0	42
228	From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert Review of Clinical Pharmacology, 2012, 5, 413-425.	1.3	23
229	Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design. RSC Drug Discovery Series, 2012, , 290-315.	0.2	3
230	How are Biogenic Amines Metabolized by Monoamine Oxidases?. European Journal of Organic Chemistry, 2012, 2012, 7057-7065.	1.2	85
231	Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6632-6635.	1.0	6
232	Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7367-7370.	1.0	10
233	Mechanistic and Structural Analyses of the Role of His67 in the Yeast Polyamine Oxidase Fms1. Biochemistry, 2012, 51, 4888-4897.	1.2	8
235	Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 4336-4347.	1.4	17
236	Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor. Brain Research, 2012, 1470, 45-51.	1.1	8
237	Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues. Bioorganic and Medicinal Chemistry, 2012, 20, 7040-7050.	1.4	24
239	Deciphering Cell Membrane Organization Based on Lateral Diffusion Measurements by Fluorescence Correlation Spectroscopy at Different Length Scales. Springer Series on Fluorescence, 2012, , 271-289.	0.8	0
240	Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A2A Receptors for the Treatment of Parkinson's Disease. Journal of Young Pharmacists, 2012, 4, 184-192.	0.1	48

#	Article	IF	CITATIONS
241	Molecular Basis of Inhibitory Activities of Berberine against Pathogenic Enzymes in Alzheimer's Disease. Scientific World Journal, The, 2012, 2012, 1-4.	0.8	46
243	Activityâ€Based Probes for Studying the Activity of Flavinâ€Dependent Oxidases and for the Protein Target Profiling of Monoamine Oxidase Inhibitors. Angewandte Chemie - International Edition, 2012, 51, 7035-7040.	7.2	63
244	8‣ubstituted 3â€Arylcoumarins as Potent and Selective MAOâ€B Inhibitors: Synthesis, Pharmacological Evaluation, and Docking Studies. ChemMedChem, 2012, 7, 464-470.	1.6	57
245	Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives. European Journal of Medicinal Chemistry, 2012, 49, 343-353.	2.6	48
246	Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. European Journal of Medicinal Chemistry, 2012, 52, 251-262.	2.6	62
247	Monoamine oxidase inhibition by C4-substituted phthalonitriles. Bioorganic Chemistry, 2012, 40, 114-124.	2.0	18
248	A scaffold hopping approach to identify novel monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1380-1383.	1.0	32
249	Monoamine oxidases in development. Cellular and Molecular Life Sciences, 2013, 70, 599-630.	2.4	58
250	Discovery, Biological Evaluation, and Structure–Activity and â^'Selectivity Relationships of 6′-Substituted (<i>E</i>)-2-(Benzofuran-3(2 <i>H</i>)-ylidene)- <i>N</i> -methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2651-2664.	2.9	56
251	Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer's disease. Journal of Molecular Graphics and Modelling, 2013, 39, 98-107.	1.3	13
252	Mitochondrial production of reactive oxygen species. Biochemistry (Moscow), 2013, 78, 1490-1511.	0.7	64
253	A comparative computational investigation on the proton and hydride transfer mechanisms of monoamine oxidase using model molecules. Computational Biology and Chemistry, 2013, 47, 181-191.	1.1	38
254	Molecular Recognition of Aromatic Rings by Flavin: Electrostatics and Dispersion Determine Ring Positioning above Isoalloxazine. Journal of Physical Chemistry A, 2013, 117, 12946-12952.	1.1	6
255	Chromenylchalcones with inhibitory effects on monoamine oxidase B. Bioorganic and Medicinal Chemistry, 2013, 21, 7890-7897.	1.4	23
256	Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids. Bioorganic and Medicinal Chemistry, 2013, 21, 7406-7417.	1.4	37
257	The Role of Biotransformation Studies in Reducing Drug Attrition. Topics in Medicinal Chemistry, 2013, , 97-137.	0.4	2
258	Design, Synthesis, inâ€vitro MAOâ€B Inhibitory Evaluation, and Computational Studies of Some 6â€Nitrobenzothiazoleâ€Derived Semicarbazones. ChemMedChem, 2013, 8, 462-474.	1.6	34
259	Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. Journal of Neural Transmission, 2013, 120, 875-882.	1.4	17

#	Article	IF	CITATIONS
260	MAO Inhibitory Activity of 2â€Arylbenzofurans versus 3â€Arylcoumarins: Synthesis, inâ€vitro Study, and Docking Calculations. ChemMedChem, 2013, 8, 956-966.	1.6	32
261	A Novel Series of 3,4â€Ðisubstituted Dihydropyrazoles: Synthesis and Evaluation for MAO Enzyme Inhibition. Journal of Heterocyclic Chemistry, 2013, 50, E87.	1.4	6
262	Up-regulation of monoamine oxidase activity in the striatum of rats following chronic treatment of thienorphine. European Journal of Pharmacology, 2013, 713, 44-46.	1.7	4
263	Reaction Mechanism of Monoamine Oxidase from QM/MM Calculations. Journal of Physical Chemistry B, 2013, 117, 14238-14246.	1.2	62
264	Similarities Between the Binding Sites of Monoamine Oxidase (MAO) from Different Species — Is Zebrafish a Useful Model for the Discovery of Novel MAO Inhibitors?. , 2013, , .		4
265	Intermolecular force between monoamine oxidase B and <i>Pseudarthria viscida</i> (L.) using atomic force spectroscopy. Journal of Experimental Nanoscience, 2013, 8, 596-605.	1.3	1
266	Structural Analysis of a Novel Cyclohexylamine Oxidase from Brevibacterium oxydans IH-35A. PLoS ONE, 2013, 8, e60072.	1.1	22
267	Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications. Current Pharmaceutical Design, 2014, 20, 155-160.	0.9	138
268	Multifunctional Enzyme Inhibition for Neuroprotection - A Focus on MAO, NOS, and AChE Inhibitors. , 2014, , 291-365.		0
269	The Inhibition of Monoamine Oxidase by Phenformin and Pentamidine. Drug Research, 2014, 64, 454-461.	0.7	2
270	Reducing Drug Attrition. Topics in Medicinal Chemistry, 2014, , .	0.4	3
271	Fluorescent Probes for Analysis and Imaging of Monoamine Oxidase Activity. Bulletin of the Korean Chemical Society, 2014, 35, 1269-1274.	1.0	5
272	Substrate profiling of cyclohexylamine oxidase and its mutants reveals new biocatalytic potential in deracemization of racemic amines. Applied Microbiology and Biotechnology, 2014, 98, 1681-1689.	1.7	32
273	Molecular modeling study on the structural basis of binding mechanism of C6-substituted phthalides with monoamine oxidases. Medicinal Chemistry Research, 2014, 23, 3624-3631.	1.1	0
274	Histone Lysine Demethylases and Their Functions in Plants. Plant Molecular Biology Reporter, 2014, 32, 558-565.	1.0	31
275	Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. , 2014, 143, 133-152.		197
276	Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues. Journal of Pharmacy and Pharmacology, 2014, 66, 677-687.	1.2	17
277	Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1104-1110.	1.1	48

ARTICLE IF CITATIONS Insight into the Functional and Structural Properties of 3â€Arylcoumarin as an Interesting Scaffold in 278 35 1.6 Monoamine Oxidaseâ€...B Inhibition. ChemMedChem, 2014, 9, 1488-1500. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy. Expert Review of 279 1.4 Neurotherapeutics, 2014, 14, 703-716. DonepezilÂ+ÂpropargylamineÂ+Â8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. European Journal of Medicinal 280 2.6 128 Chemistry, 2014, 80, 543-561. Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: Role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 389-397. Overexpression of membrane proteins from higher eukaryotes in yeasts. Applied Microbiology and 282 1.7 27 Biotechnology, 2014, 98, 7671-7698. Kinetic mechanism of putrescine oxidase from <i><scp>R</scp>hodococcusÂerythropolis</i>. FEBS Journal, 2014, 281, 4384-4393. 2.2 Oxidative stress in muscular dystrophy: from generic evidence to specific sources and targets. 284 0.9 40 Journal of Muscle Research and Cell Motility, 2014, 35, 23-36. Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with 2.9 Subnanomolar Potency. Journal of Medicinal Chemistry, 2014, 57, 6679-6703. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory 286 1.0 44 activities and docking studies. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3278-3284. A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease 5.8 models. Nature Communications, 2014, 5, 3276. New 2H-chromene-3-carboxamide derivatives: Design, synthesis and use as inhibitors of hMAO. 288 2.6 27 European Journal of Medicinal Chemistry, 2014, 80, 278-284. New coumarin derivatives: Design, synthesis and use as inhibitors of hMAO. Bioorganic and Medicinal 1.4 34 Chemistry, 2014, 22, 3732-3738. Monoamine oxidase A and B substrates: probing the pathway for drug development. Future Medicinal 290 1.1 21 Chemistry, 2014, 6, 697-717. α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2758-2763. 1.0 Quantum chemical modeling of the inhibition mechanism of monoamine oxidase by oxazolidinone and analogous heterocyclic compounds. Journal of Enzyme Inhibition and Medicinal Chémistry, 2014, 29, 292 2.510 81-86. Molecular interaction studies of green tea catechins as multitarget drug candidates for the treatment of Parkinson's disease: computational and structural insights. Network: Computation in 294 Neural Systems, 2015, 26, 97-115. Catalytic Amine Oxidation under Ambient Aerobic Conditions: Mimicry of Monoamine Oxidaseâ€...B. 295 7.2 54 Angewandte Chemie - International Edition, 2015, 54, 8997-9000. Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol. Molecules, 2015, 20, 7454-7473.

#	Article	IF	CITATIONS
297	Pichia pastoris as an expression host for membrane protein structural biology. Current Opinion in Structural Biology, 2015, 32, 9-17.	2.6	115
298	Influence of the Environment on the Oxidative Deamination of <i>p</i> -Substituted Benzylamines in Monoamine Oxidase. Journal of Physical Chemistry B, 2015, 119, 3678-3686.	1.2	24
299	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Bioorganic and Medicinal Chemistry, 2015, 23, 770-778.	1.4	26
300	Design of a structural framework with potential use to develop balanced multifunctional agents against Alzheimer's disease. RSC Advances, 2015, 5, 14242-14255.	1.7	12
301	Manipulation of the Aggregation and Deaggregation of Tetraphenylethylene and Silole Fluorophores by Amphiphiles: Emission Modulation and Sensing Applications. Langmuir, 2015, 31, 4593-4604.	1.6	84
302	Structure-Based Design and Optimization of Multitarget-Directed 2 <i>H</i> -Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases. Journal of Medicinal Chemistry, 2015, 58, 5561-5578.	2.9	89
303	Chromanones: selective and reversible monoamine oxidase B inhibitors with nanomolar potency. MedChemComm, 2015, 6, 1293-1302.	3.5	22
304	<i>cis</i> â€cyclopropylamines as mechanismâ€based inhibitors of monoamine oxidases. FEBS Journal, 2015, 282, 3190-3198.	2.2	31
305	Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 31, 1-9.	2.5	34
306	Computer modelling of monoamine oxidases. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2015, 9, 275-282.	0.2	0
307	Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B. MedChemComm, 2015, 6, 2146-2157.	3.5	9
308	Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders. Journal of Medicinal Chemistry, 2015, 58, 6710-6715.	2.9	29
309	Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 515-525.	1.4	21
310	The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes. Frontiers in Neuroscience, 2016, 10, 327.	1.4	32
311	Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Frontiers in Neuroscience, 2016, 10, 375.	1.4	55
312	Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 2016, 7, 340.	1.6	269
313	Design, Synthesis, and Evaluation of 2â€Aminoâ€6â€nitrobenzothiazoleâ€Đerived Hydrazones as MAO Inhibitors: Role of the Methylene Spacer Group. ChemMedChem, 2016, 11, 1551-1567.	1.6	23
314	Evaluation of Natural and Synthetic 1,4â€naphthoquinones as Inhibitors of Monoamine Oxidase. Chemical Biology and Drug Design, 2016, 87, 737-746.	1.5	19

#	Article	IF	CITATIONS
315	Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer. Scientific Reports, 2016, 6, 21986.	1.6	37
316	4-Organoseleno-Isoquinolines Selectively and Reversibly Inhibit the Cerebral Monoamine Oxidase B Activity. Journal of Molecular Neuroscience, 2016, 59, 135-145.	1.1	16
317	Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Advances, 2016, 6, 42660-42683.	1.7	98
318	New isoxazolidinone and 3,4-dehydro-β-proline derivatives as antibacterial agents and MAO-inhibitors: A complex balance between two activities. European Journal of Medicinal Chemistry, 2016, 124, 906-919.	2.6	20
319	Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 4835-4854.	1.4	23
320	Structural Analysis Provides Mechanistic Insight into Nicotine Oxidoreductase from <i>Pseudomonas putida</i> . Biochemistry, 2016, 55, 6595-6598.	1.2	19
321	New recombinant cyclohexylamine oxidase variants for deracemization of secondary amines by orthogonally assaying designed mutants with structurally diverse substrates. Scientific Reports, 2016, 6, 24973.	1.6	15
322	Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents. Journal of Medicinal Chemistry, 2016, 59, 6791-6806.	2.9	76
323	Anodic Oxidation of Caffeine and Theophylline in Glacial Acetic Acid. ChemistrySelect, 2016, 1, 414-416.	0.7	6
324	Discovery of 3â€Hydroxyâ€3â€phenacyloxindole Analogues of Isatin as Potential Monoamine Oxidase Inhibitors. ChemMedChem, 2016, 11, 119-132.	1.6	31
325	Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1741-1748.	1.4	14
326	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	2.9	70
327	Pharmacophore-Based 3D-QSAR Analysis of Thienyl Chalcones as a New Class of Human MAO-B Inhibitors: Investigation of Combined Quantum Chemical and Molecular Dynamics Approach. Journal of Physical Chemistry B, 2017, 121, 1186-1203.	1.2	40
328	A Green and Convenient Route for the Regioselective Synthesis of New Substituted 3-Aryl-5H-indeno[1,2-c]pyridazines as Potential Monoamine Oxidase Type A Inhibitors. Australian Journal of Chemistry, 2017, 70, 660.	0.5	6
330	MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. European Journal of Medicinal Chemistry, 2017, 131, 92-106.	2.6	65
331	Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced intoÂ2-aryl-1,3,4-oxadiazin-5(6 H)-one. European Journal of Medicinal Chemistry, 2017, 130, 365-378.	2.6	9
332	The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase. European Journal of Medicinal Chemistry, 2017, 135, 196-203.	2.6	17
333	Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease. Future Medicinal Chemistry, 2017, 9, 811-832.	1.1	44

#	Article	IF	CITATIONS
334	Multiscale simulation of monoamine oxidase catalyzed decomposition of phenylethylamine analogs. European Journal of Pharmacology, 2017, 817, 46-50.	1.7	18
335	Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. International Journal of Biological Macromolecules, 2017, 104, 1321-1329.	3.6	51
336	Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease. MedChemComm, 2017, 8, 1459-1467.	3.5	12
337	Dynamic hydrogels produced via monoamine oxidase B-catalyzed deamination and aldimine crosslinking for 3D printing. Journal of Materials Chemistry B, 2017, 5, 5092-5095.	2.9	23
338	Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2 <i>H</i> -Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure–Activity Relationships Predictive Models. Journal of Chemical Information and Modeling, 2017, 57, 787-814.	2.5	33
339	What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidaseâ€B Towards Histamine and <i>N</i> â€Methylhistamine. Chemistry - A European Journal, 2017, 23, 2915-2925.	1.7	35
340	How fast monoamine oxidases decompose adrenaline? Kinetics of isoenzymes A and B evaluated by empirical valence bond simulation. Proteins: Structure, Function and Bioinformatics, 2017, 85, 2170-2178.	1.5	15
341	MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations. MedChemComm, 2017, 8, 1788-1796.	3.5	17
342	Facile One-Pot Synthesis Methodology for Nitrogen-Containing Heterocyclic Derivatives of 3,5-Disubstituted 4,5-Dihydro-1H-Pyrazole, Their Biological Evaluation and Molecular Docking Studies. Pharmaceutical Chemistry Journal, 2017, 51, 564-575.	0.3	7
343	Synthesis, crystal structures, molecular docking, inÂvitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid. Journal of Molecular Structure, 2017, 1128, 493-498.	1.8	14
344	Rapid synthesis of flavoneâ€based monoamine oxidase (MAO) inhibitors targeting two active sites using click chemistry. Chemical Biology and Drug Design, 2017, 89, 141-151.	1.5	15
345	N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. Bioorganic and Medicinal Chemistry, 2017, 25, 633-645.	1.4	49
346	Design and Synthesis of New Benzothiazole Compounds as Selective hMAO-B Inhibitors. Molecules, 2017, 22, 2187.	1.7	29
347	Magnetic Force-Driven Graphene Patterns to Direct Synaptogenesis of Human Neuronal Cells. Materials, 2017, 10, 1151.	1.3	15
348	Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules, 2017, 22, 1192.	1.7	156
349	Investigating Rigidity Properties of Protein Cavities. , 2017, , .		0
350	Monoamine Oxidases. Sub-Cellular Biochemistry, 2018, 87, 117-139.	1.0	77
351	Monoamine oxidase-dependent endoplasmic reticulum-mitochondria dysfunction and mast cell degranulation lead to adverse cardiac remodeling in diabetes. Cell Death and Differentiation, 2018, 25, 1671-1685	5.0	54

#	Article	IF	CITATIONS
352	Kinetics, mechanism, and inhibition of monoamine oxidase. Journal of Neural Transmission, 2018, 125, 1659-1683.	1.4	65
353	Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of Their Therapeutic Activity, Pharmacokinetic and Toxicity Properties. ACS Chemical Neuroscience, 2018, 9, 1768-1782.	1.7	33
354	An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4â€ <i>f</i>]indoleâ€5,7â€dione and indoleâ€5,6â€dicarbonitrile derivatives. Drug Development Research, 2018, 79, 81-93.	1.4	8
355	90Âyears of monoamine oxidase: some progress and some confusion. Journal of Neural Transmission, 2018, 125, 1519-1551.	1.4	99
356	Recognition of trans and gauche phenylethylamine conformers in the active site of human monoamine oxidase B: A MD-simulation and DFT studies. Computational and Theoretical Chemistry, 2018, 1127, 44-51.	1.1	2
357	Severe Fertility Effects of <i>sheepish</i> Sperm Caused by Failure To Enter Female Sperm Storage Organs in <i>Drosophila melanogaster</i> . G3: Genes, Genomes, Genetics, 2018, 8, 149-160.	0.8	4
358	13 reasons why the brain is susceptible to oxidative stress. Redox Biology, 2018, 15, 490-503.	3.9	738
359	Why does the Y326I mutant of monoamine oxidase B decompose an endogenous amphetamine at a slower rate than the wild type enzyme? Reaction step elucidated by multiscale molecular simulations. Physical Chemistry Chemical Physics, 2018, 20, 4181-4188.	1.3	14
360	MAO inhibitors and their wider applications: a patent review. Expert Opinion on Therapeutic Patents, 2018, 28, 211-226.	2.4	88
361	Privileged scaffolds as MAO inhibitors: Retrospect and prospects. European Journal of Medicinal Chemistry, 2018, 145, 445-497.	2.6	122
362	Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity. Journal of Biomolecular Structure and Dynamics, 2018, 36, 1439-1462.	2.0	18
363	Monoamine oxidases inhibitors from Colvillea racemosa : Isolation, biological evaluation, and computational study. FA¬toterapA¬A¢, 2018, 124, 217-223.	1.1	14
364	Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis. Chemistry Central Journal, 2018, 12, 112.	2.6	15
365	Computational Studies Applied to Flavonoids against Alzheimer's and Parkinson's Diseases. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-21.	1.9	51
366	Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer's disease. Chemistry Central Journal, 2018, 12, 128.	2.6	47
367	Monoamine Oxidases and Flavin-Containing Monooxygenases. , 2018, , 87-125.		4
368	Insights into a dual function amide oxidase/macrocyclase from lankacidin biosynthesis. Nature Communications, 2018, 9, 3998.	5.8	17
369	An amine oxidase gene from mud crab, Scylla paramamosain, regulates the neurotransmitters serotonin and dopamine in vitro. PLoS ONE, 2018, 13, e0204325.	1.1	1

# Artic 370 Explo	CLE	IF	
370 Explo			CITATIONS
	pring Protein Cavities through Rigidity Analysis. Molecules, 2018, 23, 351.	1.7	5
371 Ň-[1-	hesis and Evaluation of -(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the tment of Diseases Belonging to MAOs. Journal of Chemistry, 2018, 2018, 1-10.	0.9	1
372 Amel	Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide liorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients. tiers in Physiology, 2018, 9, 1087.	1.3	11
373 The s 125,	structure of monoamine oxidases: past, present, and future. Journal of Neural Transmission, 2018, 1567-1579.	1.4	40
	tallography Coupled with Kinetic Analysis Provides Mechanistic Underpinnings of a tine-Degrading Enzyme. Biochemistry, 2018, 57, 3741-3751.	1.2	16
375 expre	tification of seven polyamine oxidase genes in tomato (Solanum lycopersicum L.) and their ession profiles under physiological and various stress conditions. Journal of Plant Physiology, 3, 228, 1-11.	1.6	42
	azole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomedicine and macotherapy, 2018, 106, 8-13.	2.5	36
	ibrane Reconstitution of Monoamine Oxidase Enzymes on Supported Lipid Bilayers. Langmuir, 2018, .0764-10773.	1.6	4
	imilarities between the binding sites of monoaminergic target proteins. PLoS ONE, 2018, 13,)0637.	1.1	5
	hesis and Biological Evaluation of New Thiosemicarbazone Derivative Schiff Bases as Monoamine ase Inhibitory Agents. Molecules, 2018, 23, 60.	1.7	16
	ence for a Cyanine Link Between Propargylamine Drugs and Monoamine Oxidase Clarifies the rivation Mechanism. Frontiers in Chemistry, 2018, 6, 169.	1.8	21
	gn, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine ase. Bioorganic and Medicinal Chemistry, 2018, 26, 4863-4870.	1.4	16
382 meth	rtroscopic (FT-IR, FT-Raman), quantum mechanical and docking studies on nyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine. Journal of Molecular Structure, 2019, 5, 163-174.	1.8	60
	Phenyloxazoleâ€4 arboxamide as a Scaffold for Selective Inhibition of Human Monoamine Oxidaseâ€B. nMedChem, 2019, 14, 1641-1652.	1.6	8
	gn, Synthesis and Docking Calculations of Prenylated Chalcones as Selective Monoamine Oxidase ibitors with Antioxidant Activity. ChemistrySelect, 2019, 4, 7698-7703.	0.7	19
	-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine ase B. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126677.	1.0	16
	n as promising drug for the treatment of Parkinson's disease: an assessment of MAO-B inhibitory ntial by docking, molecular dynamics and DFT studies. Molecular Simulation, 2019, 45, 1563-1571.	0.9	31
	overy of monoamine oxidase inhibitors by medicinal chemistry approaches. MedChemComm, 2019, .0-25.	3.5	38

#	Article	IF	CITATIONS
389	The Mechanism of Sugar Câ^'H Bond Oxidation by a Flavoprotein Oxidase Occurs by a Hydride Transfer Before Proton Abstraction. Chemistry - A European Journal, 2019, 25, 4460-4471.	1.7	11
390	Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. Molecular Diversity, 2019, 23, 897-913.	2.1	21
391	Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline. ACS Chemical Neuroscience, 2019, 10, 3532-3542.	1.7	40
392	Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Frontiers in Molecular Neuroscience, 2019, 12, 143.	1.4	83
393	Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study. BMC Chemistry, 2019, 13, 38.	1.6	11
394	Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1090-1093.	1.0	6
395	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1369-1382.	3.3	74
396	Exposing the Interplay Between Enzyme Turnover, Protein Dynamics, and the Membrane Environment in Monoamine Oxidase B. Biochemistry, 2019, 58, 2362-2372.	1.2	12
397	Monoamine oxidaseâ€B inhibitors as potential neurotherapeutic agents: An overview and update. Medicinal Research Reviews, 2019, 39, 1603-1706.	5.0	77
398	Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy. International Journal of Molecular Sciences, 2019, 20, 6053.	1.8	14
399	Lipid reducing potential of liposomes loaded with ethanolic extract of purple <i>pitanga</i> (<i>Eugenia uniflora)</i> administered to <i>Caenorhabditis elegans</i> . Journal of Liposome Research, 2019, 29, 274-282.	1.5	12
400	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. Progress in Neurobiology, 2019, 174, 53-89.	2.8	223
401	Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 40-46.	1.0	32
402	Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. European Journal of Medicinal Chemistry, 2019, 161, 292-309.	2.6	41
403	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. European Journal of Medicinal Chemistry, 2020, 185, 111770.	2.6	30
404	New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling. Journal of Ethnopharmacology, 2020, 248, 112305.	2.0	16
405	Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation. Bioorganic Chemistry, 2020, 94, 103477.	2.0	44
406	Beetroot supplemented diet exhibit anti-amnesic effect via modulation of cholinesterases, purinergic enzymes, monoamine oxidase and attenuation of redox imbalance in the brain of scopolamine treated male rats. Nutritional Neuroscience, 2022, 25, 1011-1025.	1.5	17

#	Article	IF	CITATIONS
407	A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. European Journal of Medicinal Chemistry, 2020, 206, 112787.	2.6	123
408	Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein–Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics. International Journal of Molecular Sciences, 2020, 21, 7648.	1.8	9
409	Integrated Binary QSAR-Driven Virtual Screening and In Vitro Studies for Finding Novel hMAO-B-Selective Inhibitors. Journal of Chemical Information and Modeling, 2020, 60, 4047-4055.	2.5	7
410	Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study. International Journal of Molecular Sciences, 2020, 21, 6151.	1.8	13
411	Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Handbook of Experimental Pharmacology, 2020, 264, 229-259.	0.9	20
412	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	7.1	70
413	Molecular Deceleration Regulates Toxicant Release to Prevent Cell Damage in Pseudomonas putida S16 (DSM 28022). MBio, 2020, 11, .	1.8	4
414	Parameters for Irreversible Inactivation of Monoamine Oxidase. Molecules, 2020, 25, 5908.	1.7	10
415	Mechanistic insights into the dual activities of the single active site of l-lysine oxidase/monooxygenase from Pseudomonas sp. AIU 813. Journal of Biological Chemistry, 2020, 295, 11246-11261.	1.6	11
416	TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology. Journal of Pharmacy and Pharmacology, 2020, 72, 1001-1012.	1.2	33
417	Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2020, 7, 12.	1.1	159
418	Asymmetric Synthesis of a Key Dextromethorphan Intermediate and Its Analogues Enabled by a New Cyclohexylamine Oxidase: Enzyme Discovery, Reaction Development, and Mechanistic Insight. Journal of Organic Chemistry, 2020, 85, 5598-5614.	1.7	9
419	Dopaminergic system contribution to the antidepressant-like effect of 3-phenyl-4-(phenylseleno) isoquinoline in mice. Behavioural Brain Research, 2020, 386, 112602.	1.2	9
420	Amphetamine Derivatives as Monoamine Oxidase Inhibitors. Frontiers in Pharmacology, 2019, 10, 1590.	1.6	20
421	Natural based piperine derivatives as potent monoamine oxidase inhibitors: an in silico ADMET analysis and molecular docking studies. BMC Chemistry, 2020, 14, 12.	1.6	14
422	Molecular docking utilising the OliveNetâ,,¢ library reveals novel phenolic compounds which may potentially target key proteins associated with major depressive disorder. Computational Biology and Chemistry, 2020, 86, 107234.	1.1	2
424	Bioinformatic Analysis of the Flavin-Dependent Amine Oxidase Superfamily: Adaptations for Substrate Specificity and Catalytic Diversity. Journal of Molecular Biology, 2020, 432, 3269-3288.	2.0	21
425	Energetic contributions of amino acid residues and its crossâ€ŧalk to delineate ligandâ€binding mechanism. Proteins: Structure, Function and Bioinformatics, 2020, 88, 1207-1225.	1.5	16

#	Article	IF	CITATIONS
426	Computational study of 3-thiophene acetic acid: Molecular docking, electronic and intermolecular interactions investigations. Computational Biology and Chemistry, 2020, 86, 107268.	1.1	38
427	N-alkylpiperidine carbamates as potential anti-Alzheimer's agents. European Journal of Medicinal Chemistry, 2020, 197, 112282.	2.6	33
428	The Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity. Antioxidants and Redox Signaling, 2021, 34, 531-550.	2.5	27
429	The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase. Molecular Diversity, 2021, 25, 491-507.	2.1	6
430	Recent advances of small molecule fluorescent probes for distinguishing monoamine oxidase-A and monoamine oxidase-B in vitro and in vivo. Molecular and Cellular Probes, 2021, 55, 101686.	0.9	6
431	Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors. Bioorganic Chemistry, 2021, 108, 104563.	2.0	7
432	Design and synthesis of novel benzyloxy-tethered-chromone-carboxamide derivatives as potent and selective human monoamine oxidase-b inhibitors. Chemical Papers, 2021, 75, 703-716.	1.0	4
433	Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. Neural Regeneration Research, 2021, 16, 2299.	1.6	17
434	Monoamine Oxidase Inhibitors in Depressive Disorders. , 2021, , 1-33.		0
435	Identification of a Potent and Selective Human Monoamine Oxidase-A Inhibitor, Glycitein, an Isoflavone Isolated from <i>Pueraria lobata</i> Flowers. ACS Food Science & Technology, 2021, 1, 538-550.	1.3	11
436	Combined 3D-QSAR and docking analysis for the design and synthesis of chalcones as potent and selective monoamine oxidase B inhibitors. Bioorganic Chemistry, 2021, 108, 104689.	2.0	26
437	Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies. Molecules, 2021, 26, 2430.	1.7	15
438	Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection. Scientific Reports, 2021, 11, 10629.	1.6	20
439	Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2022, 29, 1757-1803.	1.2	12
440	Suitable Docking Protocol for the Design of Novel Coumarin Derivatives with Selective MAO-B Effects. Journal of Molecular Docking, 2021, 1, 40-47.	0.0	1
441	Deciphering the detailed structure–activity relationship of coumarins as Monoamine oxidase enzyme inhibitors—An updated review. Chemical Biology and Drug Design, 2021, 98, 655-673.	1.5	33
442	Questions in the Chemical Enzymology of MAO. Chemistry, 2021, 3, 959-978.	0.9	5
443	DATABASE ENRICHMENTS OF MAO-B THROUGH ENSEMBLE DOCKING. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 32-35.	0.3	3

	Сіт	TATION REPORT	
#	Article	IF	CITATIONS
444	Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease. Bioorganic Chemistry, 2021, 114, 105070.	2.0	17
445	High-Throughput Screening and Molecular Dynamics Simulation of Natural Product-like Compounds against Alzheimer's Disease through Multitarget Approach. Pharmaceuticals, 2021, 14, 937.	1.7	28
446	Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation. European Journal of Medicinal Chemistry, 2021, 222, 113558.	2.6	11
447	Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies. Bioorganic Chemistry, 2021, 115, 105233.	2.0	9
448	Fast Kinetics Reveals Rate-Limiting Oxidation and the Role of the Aromatic Cage in the Mechanism of the Nicotine-Degrading Enzyme NicA2. Biochemistry, 2021, 60, 259-273.	1.2	8
449	Regulation Monoamine Oxidases. , 2021, , 542-560.		1
451	Flavins and Flavoproteins: Applications in Medicine. Methods in Molecular Biology, 2014, 1146, 113-15	57. 0.4	10
452	Overexpression of Membrane Proteins in Saccharomyces cerevisiae for Structural and Functional Studies: A Focus on the Rabbit Ca2+-ATPase Serca1a and on the Yeast Lipid "Flippase―Complex Drs2p/Cdc50p. , 2014, , 133-171.		6
453	Three-Dimensional Crystallization of Membrane Proteins. Methods in Molecular Biology, 2007, 363, 191-223.	0.4	3
454	Deprenyl: from chemical synthesis to neuroprotection. , 2006, , 143-156.		13
455	Inhibitions of monoamine oxidases and acetylcholinesterase by 1-methyl, 5-phenyl substituted thiosemicarbazones: Synthesis, biochemical, and computational investigations. Process Biochemistry, 2020, 99, 246-253.	1.8	5
456	Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. Journal of Clinical Investigation, 2005, 115, 1275-1280.	3.9	370
457	Non-P450 Mediated Oxidative Metabolism of Xenobiotics. , 2003, , 483-539.		7
458	Oxidation Pathways and the Enzymes That Mediate Them. , 2007, , 33-108.		1
459	2-pyrazoline derivatives in neuropharmacology: Synthesis, ADME prediction, molecular docking and in vivo biological evaluation. EXCLI Journal, 2017, 16, 628-649.	0.5	7
460	A Review of Recent Advances and Research on Drug Target Identification Methods. Current Drug Metabolism, 2019, 20, 209-216.	0.7	23
461	Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present. Mini-Reviews in Medicinal Chemistry, 2020, 20, 908-920.	1.1	6
462	Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Letters in Organic Chemistry, 2015, 12, 605-613	. 0.2	38

#	Article	IF	CITATIONS
463	Epigenetic and Therapeutic Analysis of various Neurological Disorders. Journal of Genetic Syndromes & Gene Therapy, 2011, 2, .	0.2	1
464	Discovery of Monoamine Oxidase A Inhibitors Derived from in silico Docking. Bulletin of the Korean Chemical Society, 2012, 33, 3841-3844.	1.0	10
465	Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies. International Journal of Biological Macromolecules, 2021, 193, 19-26.	3.6	12
466	Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development. Molecules, 2021, 26, 6019.	1.7	20
467	Design, synthesis, in vitro, and in silico studies of 1,2,4-triazole-piperazine hybrid derivatives as potential MAO inhibitors. Bioorganic Chemistry, 2021, 117, 105430.	2.0	3
468	Monoamine Oxidase B. , 2007, , 1-10.		1
469	Role of thymine in protein coding frames of mRNA sequences. Bioinformation, 2008, 2, 304-307.	0.2	5
470	Interfacial Water and Cell Architecture/Function. , 2010, , 233-246.		0
471	The antioxidant properties, cytotoxicity and monoamine oxidase inhibition abilities of the crude dichloromethane extract of Tarchonanthus camphoratus L. leaves. African Journal of Biotechnology, 2011, 10, .	0.3	3
473	Molecular docking and admet studies of 3-phenyl coumarin derivatives for their Anti ancer activity. International Journal of Pharma and Bio Sciences, 2016, 7, .	0.1	0
474	In Silico Design, Synthesis of Hybrid Combinations: Quercetin Based MAO Inhibitors with Antioxidant Potential. Current Topics in Medicinal Chemistry, 2019, 19, 156-170.	1.0	3
475	Structure of <i>Pseudomonas aeruginosa</i> spermidine dehydrogenase: a polyamine oxidase with a novel hemeâ€binding fold. FEBS Journal, 2022, 289, 1911-1928.	2.2	5
478	Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase. Bioorganic and Medicinal Chemistry, 2022, 54, 116558.	1.4	5
479	Genus Lonicera: New drug discovery from traditional usage to modern chemical and pharmacological research. Phytomedicine, 2022, 96, 153889.	2.3	12
480	Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versusÂtrans-6-Styrylcoumarin. Molecules, 2022, 27, 928.	1.7	13
481	Discovery of a new flavin N5-adduct in a tyrosine to phenylalanine variant of d-Arginine dehydrogenase. Archives of Biochemistry and Biophysics, 2022, 715, 109100.	1.4	1
482	Computational studies on the cholinesterase, beta-secretase 1 (BACE1) and monoamine oxidase (MAO) inhibitory activities of endophytes-derived compounds: towards discovery of novel neurotherapeutics. Journal of Biomolecular Structure and Dynamics, 2022, , 1-15.	2.0	3
483	Imaging of Reactive Astrogliosis by Positron Emission Tomography. Frontiers in Neuroscience, 2022, 16, 807435.	1.4	25

#	Article	IF	CITATIONS
484	Structural exploration of selected C6 and C7-substituted coumarin isomers as selective MAO-B inhibitors. Journal of Biomolecular Structure and Dynamics, 2023, 41, 2326-2340.	2.0	25
485	Positional scanning of natural product hispidol's ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 768-780.	2.5	12
486	Interaction between PET tracer and the specific residues around the gate of the open form of Monoamine Oxidase B (MAO-B). Journal of Physics: Conference Series, 2022, 2207, 012025.	0.3	0
487	Blockage of the Monoamine Oxidase by a Natural Compound to Overcome Parkinson's Disease via Computational Biology. Journal of Computational Biophysics and Chemistry, 2022, 21, 373-387.	1.0	7
488	Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1ÂH-pyrrolo-[3,2-c]quinolines. European Journal of Medicinal Chemistry, 2022, 236, 114329.	2.6	8
489	Flavin adenine dinucleotide functionalized gold nanoparticles for the electrochemical detection of dopamine. Sensors and Actuators Reports, 2022, 4, 100085.	2.3	3
490	The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update. CNS and Neurological Disorders - Drug Targets, 2023, 22, 329-352.	0.8	2
491	Isoliquiritigenin, a potent human monoamine oxidase inhibitor, modulates dopamine D1, D3, and vasopressin V1A receptors. Scientific Reports, 2021, 11, 23528.	1.6	15
497	Myricitrin – a flavonoid isolated from the Indian olive tree (<i>Elaeocarpus floribundus</i>) – inhibits Monoamine oxidase in the brain and elevates striatal dopamine levels: therapeutic implications against Parkinson's disease. Food and Function, 2022, 13, 6545-6559.	2.1	9
498	Exome sequencing of Japanese schizophrenia multiplex families supports the involvement of calcium ion channels. PLoS ONE, 2022, 17, e0268321.	1.1	0
499	Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidaseâ€B inhibitors. Archiv Der Pharmazie, 2022, 355, e2200084.	2.1	14
501	An updated patent review on monoamine oxidase (MAO) inhibitors. Expert Opinion on Therapeutic Patents, 2022, 32, 849-883.	2.4	12
502	Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma. Molecules, 2022, 27, 4297.	1.7	23
503	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics, 2022, 14, 1420.	2.0	3
504	Analgesic and Antidepressant Activity of 8-Substituted Harmine Derivatives. Chemistry of Heterocyclic Compounds, 2022, 58, 324-332.	0.6	1
505	Effect of Aqueous and Alcoholic Bee Pollen Extracts on Monoamine Oxidase Activity. Research Journal of Pharmacy and Technology, 2022, , 3731-3735.	0.2	0
506	Computational Chemistry and Molecular Modeling of Reversible MAO Inhibitors. Methods in Molecular Biology, 2023, , 221-252.	0.4	4
507	<i> In silico </i> studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA _{2A} R antagonists for the treatment of Parkinson's disease. Journal of Integrative Bioinformatics, 2022, 19, .	1.0	7

		CITATION REPORT		
#	Article		IF	CITATIONS
508	Crystallization of Human Monoamine Oxidase B. Methods in Molecular Biology, 2023,	, 115-122.	0.4	1
509	A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke. Neuro 2022, 93, 163-172.	Toxicology,	1.4	2
510	The inhibition of monoamine oxidase by harmine derivatives. Results in Chemistry, 202	2, 4, 100607.	0.9	3
511	Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Ir Seminars in Nuclear Medicine, 2023, 53, 213-229.	itricacies.	2.5	5
512	A twenty-year journey exploring coumarin-based derivatives as bioactive molecules. Fro Chemistry, 0, 10, .	ontiers in	1.8	7
513	Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docl Multi-Spectroscopy Approaches. Biomolecules, 2022, 12, 1470.	Ring and	1.8	3
515	The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones. Bioorganic a Chemistry Letters, 2022, 77, 129038.	nd Medicinal	1.0	2
516	Monoamine Oxidase Inhibitors in Depressive Disorders. , 2022, , 1347-1379.			0
517	In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitor Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson's Disease. Molecu	y Effects of Iles, 2022, 27, 8485.	1.7	2
518	Modulation of histone H3K4 dimethylation by spermidine ameliorates motor neuron su neuropathology in a mouse model of ALS. Journal of Biomedical Science, 2022, 29, .	urvival and	2.6	2
519	Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and A prediction for identification of dual targets inhibitors of Parkinson's disease with n Silico Pharmacology, 2023, 11, .		1.8	4
520	Monoamine oxidase A-dependent ROS formation modulates human cardiomyocyte dif through AKT and WNT activation. Basic Research in Cardiology, 2023, 118, .	ferentiation	2.5	8
521	Synthetic cannabinoid receptor agonists are monoamine <scp>oxidaseâ€A</scp> sele FEBS Journal, 2023, 290, 3243-3257.	ctive inhibitors.	2.2	3
522	Design of new reversible and selective inhibitors of monoamine oxidase A and a compa drugs already approved. Bulletin of the National Research Centre, 2023, 47, .	rison with	0.7	2
523	Recent updates on structural insights of MAO-B inhibitors: a review on target-based ap Molecular Diversity, 0, , .	proach.	2.1	5
524	New Indole-3-Propionic Acid and 5-Methoxy-Indole Carboxylic Acid Derived Hydrazone Multifunctional Neuroprotectors. Antioxidants, 2023, 12, 977.	Hybrids as	2.2	2
530	Computational Modeling of MAO Inhibitors as Anti-Alzheimer Agents. Neuromethods,	2023, , 325-353.	0.2	1
533	Small-molecule probes from bench to bedside: advancing molecular analysis of drugâ€ interactions toward precision medicine. Chemical Society Reviews, 2023, 52, 5706-574	"target 43	18.7	7

#	Article	IF	Citations
546	Enzyme Inhibition Assays for Monoamine Oxidase. Methods in Molecular Biology, 2024, , 329-336.	0.4	0